NCT00457470: AG-014699 for diabetic macular edema: withdrawn phase II study

NCT00457470 is Pfizer's phase II study of AG-014699 in diffuse diabetic macular edema. AG-014699 is the development code associated with rucaparib; the condition in this registration is diabetes-related retinal swelling, not an oncology indication. The planned comparison was randomized, double-blind and parallel-group in adults with central retinal involvement. 1 2

The registered measurements included retinal thickness and visual acuity, with short-term assessments around days 15 and 25. This distinction matters: an anatomical reduction in swelling would not automatically establish a meaningful improvement in sight. The inspected historical record was updated in May 2015 and marked withdrawn. 2

The useful evidence from this identifier is the documented ophthalmic development program and its protocol. The cited record does not provide an observed retinal-thickness effect, a vision benefit, or a treated-population safety estimate. Results from rucaparib cancer studies would answer a different question. 2

Sources

1. ClinicalTrials.gov — ClinicalTrials.gov — NCT00457470. Original registration; establishes the exact study identity and registered methods.Original study registration · Original record checked against the registry API. Checked 2026-10-10. Registration and current registry fields do not by themselves establish efficacy. Historical details in the article retain their stated date. Supplied note: ClinicalTrials.gov — NCT00457470. Original registration; establishes the exact study identity and registered methods.

2. ICH GCP — ICH GCP — NCT00457470. Readable reproduction of the sponsor-submitted registration, including the design and dated status fields; not an independent outcome study.Cited supporting source · Link and description preserved from supplied research. Checked in supplied research dated 2026-10-10. Source description comes from supplied research; underlying page was not independently re-read for this update.